The thiopurine drugs are purine antimetabolites widely used in the treatment of acute lymphoblastic leukemia, autoimmune disorders (e.g., Crohn's disease, rheumatoid arthritis), and organ transplant recipients.

Metabolism is catalyzed by S-methyltransferase.[1]

Litigation over patents covering diagnostic kits to monitor the dosing of these drugs led to a US Supreme Court case, Mayo Collaborative Services v. Prometheus Laboratories, Inc. that dramatically changed the nature of patent law in the United States.[2][3]

See also


  1. Sahasranaman S, Howard D, Roy S (August 2008). "Clinical pharmacology and pharmacogenetics of thiopurines". Eur. J. Clin. Pharmacol. 64 (8): 753–67. doi:10.1007/s00228-008-0478-6. PMID 18506437.
  2. Supreme Court Decision. Mayo Collaborative Services v. Prometheus Laboratories, Inc., No. 10-1150, Slip Op. at 16. Decision
  3. Gene Quinn, Killing Industry: The Supreme Court Blows Mayo v. Prometheus IP Watchdog (March 20, 2012).

This article is issued from Wikipedia - version of the 8/29/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.